BioCentury
ARTICLE | Company News

Oxigene and Techniclone cancer collaboration

March 7, 2000 8:00 AM UTC

The companies signed a letter of intent to develop and commercialize TCLN's Vascular Targeting Agent (VTA) technology with OXGN's tubulin binding compounds. VTA uses vascular endothelial growth factor...